TEGSEDI

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug TEGSEDI contains one active pharmaceutical ingredient (API):

1	Inotersen UNII 950736UC77 - INOTERSEN SODIUM
	Inotersen is an antisense oligonucleotide that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues. It is used for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
	Read more about Inotersen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TEGSEDI Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07XX15		N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	586020060000607, 586020060000707
CA	Health Products and Food Branch	02481383
EE	Ravimiamet	1778328, 1778339
ES	Centro de información online de medicamentos de la AEMPS	1181296002
FR	Base de données publique des médicaments	60789511
GB	Medicines & Healthcare Products Regulatory Agency	373338
IT	Agenzia del Farmaco	046924015, 046924027
LT	Valstybinė vaistų kontrolės tarnyba	1085961, 1085962
PL	Rejestru Produktów Leczniczych	100408465
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67656001, W67656002
US	FDA, National Drug Code	72126-007